Natriumoxybaat Aristo (Sodium Oxybate)

Sodium oxybate works by binding to and activating GABA_B receptors in the brain. This enhances inhibitory GABA signaling, producing a central nervous system depressant effect that consolidates nighttime sleep and suppresses the REM‑related mechanisms that trigger cataplexy and excessive daytime sleepiness.

The dose of sodium oxybate is individualized by the prescribing clinician based on the patient’s condition, response, and tolerability. Dosage regimens are established during medical evaluation and may be adjusted over time; patients should follow the prescriber’s instructions exactly.

Safety data for sodium oxybate in pregnancy and lactation are limited. The product is classified as having an unknown pregnancy risk, and breastfeeding is not recommended unless the potential benefit justifies the potential risk. Physicians should discuss alternatives and weigh risks carefully.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Sodium oxybate is the only medication approved specifically for cataplexy and has a unique mechanism as a GABA_B agonist. Wake‑promoting agents such as modafinil or armodafinil improve daytime alertness but do not treat cataplexy. Sodium oxybate therefore offers a broader therapeutic effect for patients with both excessive daytime sleepiness and cataplexy.

The product should be stored at ambient temperature below 25 °C, in its original packaging, protected from moisture and direct light. Keep the container tightly closed and out of reach of children. Do not refrigerate or freeze unless the manufacturer’s label specifies otherwise.

Sodium oxybate is taken orally, usually as a liquid solution or tablet, as directed by the prescriber. Doses are typically divided into two administrations per night, with the second dose taken several hours after the first, to align with the patient’s sleep schedule.

The most serious adverse events include respiratory depression, which can be life‑threatening, seizures, and severe hypotension. Patients should be monitored closely for signs of breathing difficulty, sudden loss of consciousness, or marked drops in blood pressure, especially when initiating therapy.

Sodium oxybate is contraindicated in individuals with severe respiratory disorders (e.g., sleep apnea), uncontrolled severe asthma, known hypersensitivity to the drug, or those who are unable to comply with the required dosing schedule. Caution is also advised for patients with significant hepatic or renal impairment.